Global Kidney Cancer Drugs Market 2012-2016

Global Kidney Cancer Drugs Market 2012-2016

Category : Healthcare

TOLL FREE
+1-971-202-1575
------------ Or -------------
help@researchbeam.com

TechNavio’s analysts forecast the Global Kidney Cancer Drugs market to grow at a CAGR of 13.4 percent over the period 2012-2016. One of the key factors contributing to this market growth is the growing demand in developing economies. The Global Kidney Cancer Drugs market has also been witnessing an increase in R&D activities. However, over-dependence of the market on the US could pose a challenge to the growth of this market. 

TechNavio’s report, Global Kidney Cancer Drugs Market 2012-2016, has been prepared based on an in-depth market analysis of the market with inputs from industry experts. The report covers the Americas, and the EMEA and APAC regions; it covers the Global Kidney Cancer Drugs market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market.

The key vendors dominating this market space are AVEO Pharmaceuticals Inc., Bayer AG, GlaxoSmithKline plc, Hoffmann-La Roche Ltd., Novartis AG, and Pfizer Inc.

The other vendors mentioned in the report are AstraZeneca plc, Onyx Pharmaceuticals Inc., Merck Serono S.A., and WILEX AG

Key questions answered in this report:
What will the market size be in 2016 and what will the growth rate be?
What are the key market trends?
What is driving this market?
What are the challenges to market growth?
Who are the key vendors in this market space?
What are the market opportunities and threats faced by the key vendors?
What are the strengths and weaknesses of each of these key vendors?

01. Executive Summary

02. Introduction

03. Market Coverage


Market Overview

Key Offerings

04. Market Landscape

04.1 Market Size 

04.2 Market Forecast

04.3 Market Segmentation

04.4 Five Forces Analysis

05. Geographical Segmentation

06. Key Leading Countries


US

Germany

Japan

07. Rate of Incidence and Prevalence

08. Vendor Landscape

09. Buying Criteria

10. Market Growth Drivers

11. Drivers and Their Impact

12. Market Challenges

13. Impact of Drivers and Challenges

14. Market Trends

15. Key Vendor Analysis


15.1 AVEO Pharmaceuticals Inc.

Business Overview

Key Information

SWOT Analysis

15.2 Bayer AG

Business Overview

Key Information

SWOT Analysis

15.3 GlaxoSmithKline plc

Business Overview

Key Information

SWOT Analysis

15.4 Hoffmann-La Roche Ltd. 

Business Overview

Key Information

SWOT Analysis

15.5 Novartis AG

Business Overview

Key Information

SWOT Analysis

15.6 Pfizer Inc.

Business Overview

Key Information

SWOT Analysis

16. Other Reports in this Series



List of Exhibits 

Exhibit 1: Global Kidney Cancer Drugs Market 2012–2016 (US$ billion)

Exhibit 2: Kidney Cancer by Category Segmentation

Exhibit 3: Global Kidney Cancer Drugs Market by Category Segmentation 2012

Exhibit 4: Global Kidney Cancer Drugs Market by Geographical Segmentation 2012

Exhibit 5: Global Kidney Cancer Drugs Market by Vendor Segmentation 2012

Exhibit 6: Business Segmentation of AVEO Pharmaceuticals Inc.

Exhibit 7: Business Segmentation of Bayer AG

Exhibit 8: Business Segmentation of GlaxoSmithKline plc

Exhibit 9: Business Segmentation of Hoffmann-La Roche Ltd.

Exhibit 10: Business Segmentation of Novartis AG

Exhibit 11: Business Segmentation of Pfizer Inc.



 


Enquiry Before Buy
image
Can´t read the image ? refresh here.